Abstract:Background: Epilepsy's pathogenesis and progression are significantly influenced by neuroinflammation, blood–brain barrier function, and synaptic remodeling function. Matrix metalloproteinase 9 (MMP-9), as a critical factor, may contribute to the development of epilepsy through one or more of the above-mentioned pathways. This study aims to evaluate and quantify the correlation between MMP-9 levels and epilepsy. Methods: We conducted a comprehensive search of Embase, Web of Science, PubMed, Cochrane Library, WanFang DATA, VIP, and the CNKI to identify studies that investigate the potential association between MMP-9 and epilepsy. The data were independently extracted by two researchers and assessed for quality using the Cochrane Collaboration tool. The extracted data were analyzed using Stata 15 and Review Manager 5.4. The study protocol was registered prospectively at PROSPERO, ID: CRD42023468493. Results: Thirteen studies with a total of 756 patients and 611 matched controls met the inclusion criteria. Eight of these studies reported total serum MMP-9 levels, and the other five studies were used for a further subgroup analysis. The meta-analysis indicated that the serum MMP-9 level was higher in epilepsy patients (SMD = 4.18, 95% confidence interval = 2.18–6.17, p < 0.00001) compared with that in the control group. Publication bias was not detected according to Begg's test. The subgroup analysis of country indicated that the epilepsy patients in China, Poland, and Egypt had higher levels of serum MMP-9 than the control group, with the increase being more pronounced in Egypt. The subgroup analysis of the age category demonstrated that the serum MMP-9 levels of the adult patients with epilepsy were significantly higher than those of the matched controls. However, the serum MMP-9 levels did not significantly differ in children with epilepsy. The subgroup analysis of the seizure types demonstrated substantial difference in the MMP-9 levels between patients of seizure-free epilepsy (patients who have been seizure-free for at least 7 days) and the control group. Meanwhile, the serum MMP-9 level in patients with epileptic seizures was significantly higher than that in the control group. The subgroup analysis based on seizure duration in patients showed that the serum MMP-9 levels at 1–3, 24, and 72 h after seizure did not exhibit significant differences between female and male patients with epilepsy when compared with the control group. The serum MMP-9 levels at 1–3 and 24 h were significantly higher than those of the matched controls. Nevertheless, the serum MMP-9 level at 72 h was not significantly different from that in the control group. Conclusion: This meta-analysis presents the first comprehensive summary of the connection between serum MMP-9 level and epilepsy. The MMP-9 levels in epilepsy patients are elevated. Large-scale studies with a high level of evidence are necessary to determine the exact relationship between MMP-9 and epilepsy.

Serum SIRT3 levels in epilepsy patients and its association with clinical outcomes and severity: A prospective observational study

Concentration of IL-1β, IL-7, IL-12, IL-17, CX3CL1, ITAC and relation with the seizure severity and sudden unexpected death in epilepsy patient

Elevated Serum Matrix Metalloproteinase-9, Interleukin-6, Hypersensitive C-Reactive Protein, and Homocysteine Levels in Patients with Epilepsy.

Expression and Correlation of the NOD-like Receptor Family, Pyrin Domain-Containing 3 Inflammasome and the Silent Information Regulator 1 in Patients with Drug-Resistant Epilepsy

Sirtuin 3 regulates astrocyte activation by reducing Notch1 signaling after status epilepticus

Inflammatory and neurotrophic factor plasma levels are related to epilepsy independently of etiology

Circulating irisin and chemerin levels as predictors of seizure control in children with idiopathic epilepsy

Reduced serum neurotrophic factors and monoamine neurotransmitters in epilepsy patients with comorbid depression

Serum endocan and preoperative systemic inflammatory markers in patients with epilepsy

Serum biomarkers in patients with drug-resistant epilepsy: a proteomics-based analysis

Increased Serum S100B Levels in Patients with Epilepsy: A Systematic Review and Meta-Analysis Study

Elevated Blood C-Reactive Protein Levels in Patients With Epilepsy: A Systematic Review and Meta-Analysis

Neuronal SIRT3 Decline Mediates Sepsis-Associated Encephalopathy Through Microglia Activation

Correlation between inflammatory markers over time and disease severity in status epilepticus: a preliminary study

Alteration of Plasma Cytokines in Patients with Active Epilepsy

Meta-analysis of MMP-9 levels in the serum of patients with epilepsy

Evaluation of Serum Matrix Metalloproteinase-3 As A Biomarker for Diagnosis of Epilepsy

Astrocyte-derived SerpinA3N promotes neuroinflammation and epileptic seizures by activating the NF-κB signaling pathway in mice with temporal lobe epilepsy

Inflammation and iron metabolism in adult patients with epilepsy: Does a link exist?

Association of High Plasma Levels of Serpin E1, IGFBP2, and CCL5 with Refractory Epilepsy in Children by Cytokine Profiling.

Correlation of serum Hcy metabolism with nerve cytokine and apoptosis molecule levels in patients with epilepsy